北京观韬律师事务所 关于北京康乐卫士生物技术股份有限公司 2024年年度股东会的 法律意见书 观意字〔2025〕第 001123 号 致：北京康乐卫士生物技术股份有限公司 北京观韬律师事务所（以下简称"本所"）受北京康乐卫士生物技术股份有限 公司（以下简称"公司"）之委托，指派本所律师出席公司2024年年度股东会（以 下简称"本次股东会"），并依据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》（以 下简称"《股东会规则》"）以及公司现行有效的《公司章程》的有关规定，出具 本法律意见书。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承担相应法律责任。 本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席会议人 员资 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2025-071 （一）会议召开情况 1.会议召开时间：2025 年 5 月 20 日 2.会议召开地点：北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 公司会议室 3.会议召开方式：现场与网络投票相结合的方式 4.会议召集人：董事会 5.会议主持人：董事长刘永江先生 北京康乐卫士生物技术股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 6.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 11 人，持有表决权的股份总数 91,199,479 股，占公司有表决权股份总数的 32.46%。 其中通过网络投票参与本次股东会的股东共 3 人，持有表决权的股份总数 101,118 股，占公司有表决权股份总数的 0.04%。 ...

Group 1 - The report highlights the second adjustment of the North Exchange 50 Index in 2025, effective on June 16, 2025, with potential new additions including Lierda, Tongguan Mining Construction, Wanda Bearings, Juxing Technology, and Yinuowei [4][10][12] - The report discusses the revision of restructuring rules by the North Exchange, introducing a "small-scale fast" review mechanism and simplified review procedures, aimed at enhancing the efficiency of mergers and acquisitions for innovative SMEs [7][8][9] - The overall PE ratio of North Exchange A-shares has rebounded to 51X, with average daily trading volume increasing to 349 billion yuan, indicating improved market sentiment [17][20] Group 2 - The report suggests that institutional investors in the North Exchange market should adopt a cautious approach, focusing on long-term stable growth companies and sectors aligned with national policies such as "self-control" and innovation-driven development [14] - Key sectors to watch include high-end manufacturing, infrastructure with high dividends, and specialty consumer industries, as well as recent hot themes like AI and robotics [14] - The report notes that the North Exchange 50 Index has increased by 3.13% this week, outperforming other indices, with a year-to-date increase of 37% [22][24]

证券代码：833575 证券简称：康乐卫士 公告编号：2025-070 北京康乐卫士生物技术股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 活动时间：2025 年 5 月 15 日 15:00-16:30 活动地点：本次业绩说明会采用网络方式举行，公司在上海证券报·中国证 券网路演中心（https://roadshow.cnstock.com/）召开了 2024 年年度报告业绩说明 会。 参会单位及人员：通过网络方式参加公司本次业绩说明会的投资者 上市公司接待人员： 公司董事长、首席科学官：刘永江先生 公司副董事长、首席资本官：李辉女士 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 公司首席财务官：董微女士 公司董事会秘书：任恩奇先生 公司保荐代表人：赵洞天先生 三、 投资者关系活动主要内容 本次业绩说明会公司就投资者普遍关注的问题进行了沟通与交流，主要问题 及 ...

Group 1: Investor Relations Activity - The investor relations activity was an earnings briefing held online on May 15, 2025, from 15:00 to 16:30 [3] - Key participants included the Chairman, Chief Scientific Officer, Chief Capital Officer, Chief Financial Officer, and the Board Secretary [3] Group 2: HPV Vaccine Development - The three-valent HPV vaccine was included in the priority review list by the National Medical Products Administration (NMPA) in March 2025, with the application accepted in April 2025 [4][5] - The review period for the three-valent HPV vaccine is shortened from 200 working days to 130 working days due to priority review [4] - The nine-valent HPV vaccine for female indications is currently undergoing phase III clinical trials, with the 42 and 48-month visits ongoing [6] - The nine-valent HPV vaccine for male indications is also in phase III trials, with 18 and 24-month visits currently being conducted [6][10] Group 3: Regulatory and Market Strategy - The company is actively communicating with the NMPA to ensure compliance and expedite the review process for the nine-valent HPV vaccine [8] - The nine-valent HPV vaccine (female indication) is expected to submit its Biologics License Application (BLA) soon, with the timeline being a few months behind the three-valent vaccine [7] - The company has adjusted its strategy in Indonesia from building a manufacturing base to collaborating with local partners for registration and market access [13][14] Group 4: Financial and Funding Strategies - The company plans to address funding shortages through various financing channels, including equity and debt financing, while maintaining high R&D investment [16] - A loan of up to 477 million yuan is being organized by a banking syndicate, with approval completed by the lead bank [19] - The company aims to enhance cash flow management and reduce operational costs to improve financial stability [18][20]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：833575 证券简称：康乐卫士 公告编号：2025-069 北京康乐卫士生物技术股份有限公司 2024 年年度报告业绩说明会预告公告 一、 说明会类型 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在北京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》 及《2024 年年度报告摘要》，为方便广大投资者更深入了解公司 2024 年年度经 营业绩的具体情况，加强与投资者的互动交流，公司拟召开 2024 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30。 本次业绩说明会将采用网络方式举行，投资者可登陆上海证券报·中国证券 网路演中心（https://roadshow.cnstock.com/）参与本次年报业绩说明会。 三、 参加人员 为充分尊重投资者、提升交流的针对性，现就公司 2024 年年度 ...

Core Insights - The report predicts adjustments to the North Exchange 50 Index on June 16, 2025, with a review cutoff date of May 16, 2025 [3] - The predicted stocks to be added to the index include Lierda, Tongguan Mining Construction, Wanda Bearings, Juxing Technology, and Yinuowei, while stocks to be removed include Guangsha Environmental Energy, Kangle Health, Tianfang Biao, Tongxiang Technology, and Kaide Quartz [3][4] - Historical data shows that stocks added to the index have an 80% probability of outperforming the index in the five trading days leading up to the adjustment, with an average excess return of 4.7%, while stocks removed have an 80% probability of underperforming, with an average excess return of -2.4% [3][6] Stock Adjustments - The average daily trading volume and market capitalization for the past six months were used to determine the adjustments, with specific figures for each stock listed [4][5] - The stocks being added have varying average daily trading volumes, with Lierda at 22,484 thousand CNY and a market cap of 5.6 billion CNY, while stocks being removed have lower trading volumes, such as Guangsha Environmental Energy at 4,710 thousand CNY and a market cap of 2.64 billion CNY [4] Impact Coefficients - The report calculates the impact coefficients for the stocks being added and removed from the index, with Tongguan Mining Construction having the highest impact coefficient of 1.86 among the new additions, and Kangle Health having the highest at 7.36 among the removals [3][9] - The impact coefficients are derived from the ratio of stock weight to average daily trading volume, indicating the potential influence of these stocks on the index [3][9]

Core Viewpoint - 康乐卫士 is currently in a loss-making state with no products commercialized, reporting a revenue of 885,600 yuan in 2024, a decrease of 50.24% year-on-year, and a net profit of -357 million yuan, down 18.51% year-on-year [1] Group 1: Financial Performance - In 2024, 康乐卫士 reported a revenue of 885,600 yuan, a decline of 50.24% compared to the previous year [1] - The net profit attributable to the parent company was -357 million yuan, representing a year-on-year decrease of 18.51% [1] - The operating cash flow was -125 million yuan, indicating a reliance on external financing for working capital [3] Group 2: Research and Development - 康乐卫士 has a total of 9 vaccine candidates in development, including 8 recombinant protein candidates and 1 mRNA candidate [2] - Key products such as the trivalent HPV vaccine and the nine-valent HPV vaccines for both female and male indications have entered Phase III clinical trials [2] - The trivalent HPV vaccine's market approval application has been accepted by the National Medical Products Administration (NMPA) and is included in the priority review process [2] Group 3: Operational Strategy - 康乐卫士 is transitioning towards becoming a commercial pharmaceutical company and has established a production base in Kunming that meets GMP standards, with an annual production capacity of 10 million doses of the trivalent HPV vaccine and 30 million doses of the nine-valent HPV vaccine [2] - The company has introduced a systematic response plan to address the risk of insufficient working capital, which includes accelerating HPV vaccine development and commercialization, optimizing asset utilization, actively seeking financing, and enhancing internal management to reduce costs and increase efficiency [3] Group 4: Recent Developments - In the first quarter of 2024, 康乐卫士 reported a 90.51% decline in revenue, while the net profit attributable to the parent company increased by 18.12% year-on-year [4]

2024 年度独立董事述职报告（乔友林） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 作为北京康乐卫士生物技术股份有限公司（以下简称"公司"）的独立董事， 本人在任职期间严格按照《公司法》《上市公司独立董事管理办法》《北京证券交 易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号——独立董 事》等有关法律法规及《公司章程》《独立董事工作制度》的规定和要求，认真、 勤勉履行职责，积极出席相关会议和参与公司重大事项决策，客观、公正、审慎 地发表意见，充分发挥了独立董事的作用。现就 2024 年度履职情况汇报如下： 一、独立董事基本情况 （一）独立董事工作履历、专业背景以及兼职情况 证券代码：833575 证券简称：康乐卫士 公告编号：2025-048 北京康乐卫士生物技术股份有限公司 乔友林，中国国籍，美国永久居留权，男，出生于 1955 年 4 月，博士研究 生学历。1991 年 9 月至 1997 年 8 月于美国国立卫生研究院和国家癌症研究所癌 症预防控制部担任正式研究雇员和博士后； ...

证券代码：833575 证券简称：康乐卫士 公告编号：2025-047 北京康乐卫士生物技术股份有限公司 2024 年度独立董事述职报告（李晓静） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 作为北京康乐卫士生物技术股份有限公司（以下简称"公司"）的独立董事， 本人在任职期间严格按照《公司法》《上市公司独立董事管理办法》《北京证券交 易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号——独立董 事》等有关法律法规及《公司章程》《独立董事工作制度》的规定和要求，认真、 勤勉履行职责，积极出席相关会议和参与公司重大事项决策，客观、公正、审慎 地发表意见，充分发挥了独立董事的作用。现就 2024 年度履职情况汇报如下： 一、独立董事基本情况 （一）独立董事工作履历、专业背景以及兼职情况 李晓静，中国国籍，无境外永久居留权，女，出生于 1972 年 8 月，博士研 究生学历，注册会计师、注册税务师、注册资产评估师。1997 年 7 月至今任北京 科技大学教师职位；2021 年 11 月至今任公 ...